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Introduction
Behcet disease (BD) is a chronic systemic inflammatory
disease of unknown origin. Although,the clinical feature of
juvenil BD is similar to adults, neurologic and gastrointest-
inal involvement have concluded more in juvenile BD.
Objectives
To evaluate the efficacy and safety of immunosuppressive
therapy including conventional therapy and anti-tumor
necrosis factor-alpha (anti-TNF-a) agents in pediatric
patients in Behcet uveitis.
Methods
A retrospective study was made of 6 consecutive pediatric
patients with BD. Inclusion criteria were fulfillment of the
classification criteria of the International Study Group for
Behçet Disease and onset of uveitis at 16 years of age or
younger. The main outcome measures were sex, age at
onset of uveitis, the initial symptom of Behcet disease,
clinical ocular features, ocular complications and systemic
treatment.
Results
Four patients were female, 2 male were. Mean age at onset
of uveitis was 11.8±3.2(7 to16) years. The most common
extra-ocular clinical manifestations were recurrent oral
ulcer in all patients and arthritis in 4 patients (50%) and
pseudo folliculitis in 3 patients (66.7%). Pan uveitis was
bilateral in 83.3%, retinal vasculitis and retinitis were seen
in 83.3% and 100% of the involved eyes, respectively.
Cataract, maculopathy, glaucoma and optic atrophy were
seen in 36.4%, 18.1%, 18.1 and 0.9 %of the involved eyes,
respectively.
Treatment modalities applied to treat either uveitis or its
complications were classified as topical, and systemic.
Corticosteroid drops (dexamethasone 0.1%, prednisolone
1%) with frequent instillation and cycloplegic drops (cyclo-
pentholate 1%) 3 times daily were used in eyes with panu-
veitis. Systemic corticosteroid treatment was performed to
suppress acute inflammatory episodes.
The mean duration of oral corticosteroid therapy for
the treatment of acute inflammatory conditions was 3.4
± 0.5 months (range, 3-4). All patients had used conven-
tional immunosuppressive (IS) agents including
azathioprine and cyclosporine, and 4 (66.7%) patients
had additionally used anti-TNF treatment to control
panuveitis attacks. Before starting to anti-TNF agents,
screening for latent tuberculosis was performed using
the local guideline.The majority of the patients (n:3)
received only ADA subcutaneous injections once in
every two weeks, while the one patient switched from
IFX to ADA due to loss of clinical response. Ocular
manifestations (panuveitis and retinal vasculitis)
responded rapidly and reduction in the number and
dose of standard immunosuppressive agents in patients
with adalimumab. Overall, mean treatment period for
anti-TNF agents was 9.5 ± 4.1 (range 6 to 14) months.
Considering the 8 eyes of 4 patients with these anti-
TNF agents, basal uveitis relapse rate of 4.0±0.8
decreased to 0.5±1.0 (p<0.05) during fallow-up. In 2
patients who completed the first year of anti-TNF treat-
ment without any relapses, anti-TNF treatment could be
stopped only in a single case using ADA, while anti-
TNF treatment had to be continued in other. No
adverse effect requiring cessation of anti-TNF agents
was observed.
Conclusion
In line with the previous data, our findings also suggest
that anti TNF alpha agents may be tried in the treatment
of pediatric Behçet uveitis resistant to other therapeutic
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